Table 1.
Demographics of the study cohorts and geometric mean PRNT50 antibody titres to SARS-CoV-2 Omicron subvariants.
| Exposure group | n | Mean Age (SD) | Age range | Male: female | WT GMT (95% CI) | BA.1 GMT(95% CI) | BA.2 GMT(95% CI) | BA.2.12.1 GMT (95% CI) | BA.4 GMT (95% CI) | BA.5 GMT (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| BNT162b2 (3 doses) | 20 | 49.5 (14.8) | 22–72 | 11:9 | 320 (320–320) |
67.3 (45.5–99.6) |
95.1 (73.7–122.8) |
69.6 (52.1–93.1) |
28.3 (21.2–37.7) |
20.7 (17.0–25.2) |
| CoronaVac (3 doses) | 20 | 49.8 (7.9) | 36–68 | 4:16 | 65.0 (1.0) | 8.1 (8.0) | 9.3 (7.0) | 5.3 (12.3) | 5.4 (12.0) | 5.4 (12.0) |
| CoronaVac (2 dose + BNT162b2 third dose) | 20 | 48.4 (9.2) | 31–66 | 10:10 | 309.1 (287.5–332.4) |
51.0 (32.9–79.0) |
46.0 (29.2–72.3) |
49.3 (31.9–76.1) |
23.8 (15.9–35.7) |
14.6 (10.1–21.2) |
| SARS-CoV-2 (ancestral) Convalescent | 20 | 48.7 (15.0) | 20–70 | 7:13 | 82.8 (58.0–118.3) |
8.1 (5.5–12.1) |
9.0 (6.7–12.2) |
7.8 (5.9–10.4) |
6.8 (5.0–9.3) |
5.9 (5.0–7.1) |
| BA.2 breakthrough infection (convalescent) | 17 | 47.1 (17.8) | 24–73 | 9:8 | 166.7 (91.7–302.8) |
70.8 (32.2–155.9) |
98.1 (52.4–183.6) |
98.1 (49.9–192.8) |
36.9 (18.3–74.3) |
36.9 (19.7–69.1) |
| Unvaccinated + BA.2 infection (convalescent) | 7 | 68.1 (7.9) | 56–82 | 4:3 | 6.7 (4.8–9.5) |
9.1 (4.2–19.7) |
24.4 (9.3–63.6) |
32.8 (16.1–67.0) |
8.2 (5.1–13.3) |
11.0 (6.2–19.7) |